KAIST researchers develop GB2Ab antibody to treat cancer cachexia in mice
A research team at KAIST has developed GB2Ab, a therapeutic antibody candidate that blocks signals responsible for appetite suppression, weight loss, and muscle wasting in cancer cachexia. The antibody successfully reversed weight and muscle loss in mouse models.
